

ImmunoPrecise Antibodies Ltd

08:30 14 Apr 2020

ImmunoPrecise Antibodies says subsidiary Talem Therapeutics enters research license agreement with Janssen Research & Development

ImmunoPrecise Antibodies Ltd. (CVE:IPA) (OTCQB:IPATF) said its subsidiary Talem Therapeutics has entered into a research license agreement with Janssen Research & Development, LLC providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target.

Under the agreement, ImmunoPrecise - a global leader in therapeutic antibody discovery and development - said Janssen holds an option to acquire all commercial rights to the antibodies. The financial details of the transaction have not been disclosed.

READ: ImmunoPrecise Antibodies and its AI collaborator team up on research program to help fight coronavirus

Ilse Roodink, chairwoman of Talem's Scientific Advisory Committee and Scientific Director at ImmunoPrecise Antibodies Europe said: "This Agreement validates Talem's business concept in early antibody discovery and development."

She added: "It is a significant milestone to see this exclusive agreement through Talem finalized with Janssen, a company so well positioned to further develop and maximize the potential of these lead candidates for clinical applications."

Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation, and rare/ specialty diseases.

Jennifer Bath, president and CEO of ImmunoPrecise Antibodies added: "Talem continues to build a therapeutic program pipeline for commercial partnering, thus optimizing shareholder value creation based on IPA's infrastructure across Europe and North America."

ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients.

Price: 2.44

Market Cap: \$195.14 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: IPA

Listing: TSX-V

52 week	High	Low
	3.14	0.5

Sector: Pharma & Biotech

Website: immunoprecise.com

Company Synopsis:

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).